Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen in Infantile-onset Spinal Muscular Atrophy (ENDEAR)
NCT02193074Phase 3Terminated
- Sponsor
- Biogen
- Start
- Aug 2014
- Primary completion
- Nov 2016
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 13
01
Overview
A Phase 3 trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Started Aug 2014; status: terminated.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02193074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02193074.